UnitedHealth Group Inc

UNH has broken below critical horizontal support and entered a Stage 4 decline, trading under its major EMAs and SMAs. The medium-term bias remains bearish, and despite extreme oversold conditions, there is no clear signal of a sustained reversal. Execution should be deferred, trimming into any rally toward the declining 9/20 EMAs and 50 SMA in the 391–396 resistance area.

• ↑Adjusted EPS jumped 56% YoY to $6.38 in Q2
• ↑Q2 revenue reached $112 B, topping expectations and showcasing scale
• ↓Commercial segment faces >11% medical cost trend, squeezing margins